Source link : https://newshealth.biz/health-news/new-il-7-antagonist-lusvertikimab-shows-uc-efficacy/
BERLIN — Lusvertikimab, a first-in-class interleukin 7 (IL-7) receptor antagonist, demonstrated clinical and endoscopic efficacy in patients with moderate to severe ulcerative colitis (UC) in the 10-week induction period of a randomized, placebo-controlled, phase 2 clinical trial. Lusvertikimab is unique in targeting the IL-7 receptor, a key player in immune-mediated inflammation. “We have a new mode […]
Author : News Health
Publish date : 2025-02-26 13:15:10
Copyright for syndicated content belongs to the linked Source.
inHealth